Posted in Jobs, News
Naynesh Mistry is looking to recruit a Product Characterisation Manager, to join a biopharmaceutical development organisation to work at their site in the North West on a permanent basis.
This Product Characterisation Manager position will provide expert technical guidance in the area of protein and carbohydrate chemistry and characterization in support of business objectives. This role will be responsible for undertaking complex analytical investigative projects and for keeping abreast of scientific developments in the protein and carbohydrate sciences area. This position will evaluate emerging technologies to drive new/improved service offerings and provide expert scientific advice to support company business. This role will require in-depth scientific understanding as well as hands-on experience regarding key analytical techniques. Those include state-of-the-art sample preparation techniques, analysis of mono-, di-, oligo-, and polysaccharides by applying techniques such as HPLC, CE, IEC, SEC as well as advanced protein characterization by applying techniques such as HPLC, LC-MS, Electrophoresis and Bio-analysis. It will also include complex data/result interpretation. Materials to be analysed will include a range of in-process, bulk drug substance and formulated products.
The responsibilities of this Product Characterisation Manager role will include:
- Provide protein and carbohydrate sciences expert support to the Analytical Group.
- Actively guide a portfolio of analytical techniques to ensure up to date and product tailored characterization capabilities.
- Manage a small team of technical/scientific professionals in assigned area.
- Ensure continuous development of technical skills and knowledge on products and processes within the Analytical team. Train/mentor junior staff.
The successful candidate for this Product Characterisation Manager role will have the following:
- A science based degree BSc/MSc or PhD preferred significant work (including laboratory) experience in area of expertise.
- Proven track record of scientific/technical achievements relevant for position. Demonstrated innovation and technical leadership skills.
- Demonstrated team management and development skills.
- Proven ability to solve complex analytical problems.
- In-depth knowledge of complex analytical data & ability to apply scientific rationale to providing practical technical solutions.
- Excellent communication skills and proven track record of presenting research projects or other scientific data at seminars and other scientific symposia.
- High degree of autonomy.
Also the candidate will preferably have knowledge of biopharmaceutical and bio similar manufacturing processes & technologies with an ability to apply scientific rationale to providing practical technical solutions.
How to apply:
For more information or to apply for this Product Characterisation Manager role please contact Naynesh Mistry on 0114 283 9956 or email firstname.lastname@example.org. Please quote reference SH22971 in all correspondence.
Posted in Industry News, Mobile News, News
Biopharmaceutical company Quintiles is looking to establish more UK sites, creating pharmaceutical and clinical jobs, reports pharmatimes.com.
The US company sees the UK as a good place for clinical trials and is hoping to open at least two more Prime Sites to go alongside the one at Queen Mary, University of London. Including two other current sites, Quintiles employs 2,000 people in the UK, a figure set to rise with the planned opening of the new Prime Sites.
Lindy Jones, Quintiles head of global integrated site services, says the UK is of “significant interested to us,” with fifty trials currently being run at the Queen Mary site. Jones believe that the UK “has opened up far more to clinical research” in the past eighteen months, meaning that Quintiles is considering opening “an additional two, maybe three Prime Sites in the UK.”
Looking for a job in the science industry? Start by clicking here, now
Posted in General, News
A new multi-million pound state-of-the-art biotechnology facility for the global biopharma company Pfizer was opened by the Science Minister, David Willets today.
The new facility is based at the pharmaceutical company’s Havant site and has cost £26.3 million. This is a significant investment by Pfizer and is evidence to the UK’s strengths in life sciences and the pool of highly skilled pharmaceutical workers we have to offer. In fact, in 2009/2010, the UK alone attracted 173 life sciences investment projects, generating nearly 8,500 jobs.
Science Minister, David Willets stated, “Pfizer’s commitment to the UK is a big win for our life science and manufacturing base. I’m hugely encouraged that even in these tough economic times the world’s largest research-based biopharmaceutical company has chosen the UK to make this significant investment.
“The Government is determined to ensure that the UK has one of the leading business environments in the world for the life sciences and remains a global force in this field.”
Are you looking for a new role in the UK pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.
Posted in General, News
The biopharmaceutical company, Gilead Sciences, has taken the decision to close its research and development operations in Durham, North Carolina. The closure will lead to biotechnology job cuts.
The company plans to close its Durham operations by the end of the year. They plan to consolidate its research and development work on treatments for hepatitis B and C to its headquarters in Foster City, California.
The biopharmaceutical company employs around 4,000 people around the world and it’s annual revenues surpassed $7 billion. Their primary areas of research include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
Looking for a new position in the biotechnology industry? Click here to search our current biotechnology jobs now.
Posted in General, News
The biopharmaceutical services provider, Quintiles have announced that it will be investing up to $2m in the Australia-based Prana Biotechnology.
Quintiles has been involved with Prana’s work since the company was established in 1997. However, recently Quintiles has subscribed to Prana’s newly subscribed shares in a bid to help support a planned definitive Phase II study with PBT2 (Prana’s lead compound for Alzheimer’s disease).
Speaking of the investment, a spokesperson from Prana stated the company was “delighted to have secured an organisation of the calibre and influence of Quintiles as a significant shareholder and supporter of Prada’s therapeutic goals”.
Are you looking for a job in science? Click here to search our current science jobs now.
Posted in General, News
This year, the DIA (Drug Information Association) chose Monaco and its state-of-the-art Grimaldi Forum to hold it’s 22nd Annual EuroMeeting, and CK Clinical, sister company of CK Science, had the pleasure of attending.
The DIA Annual EuroMeeting is the largest event of its kind in Europe. From the 8-10th March 2010, 3,000 professionals from biopharmaceutical industry, contract service organisations, academic research centres, regulatory agencies, health ministries, patient organisations and trade associations, descended on Monaco.
CK Clinical’s first visit to the DIA Conference was a resounding success. Pharmaceutical jobs were brought in across all sectors, and the conference definitely acted as a brilliant springboard kick off our campaign to enter the European market.
We also ran a prize draw to win an Apple iPod Touch, the winner being a Departmental Manager from Novo Nordisk in Denmark. Thank you to everybody that entered.
The Grimaldi Forum was an impressive waterfront venue, filled with daylight and a stunning glass entrance. A perfect venue to network with clients. Monaco was incredible with Ferrari’s, Mercedes Benz and Bentleys everywhere you looked. The hotel even had its own helipad!
We are very much looking forward to attending and exhibiting at next year’s DIA Conference in Geneva.
Posted in General, News
The world-class pharmaceutical company, GlaxoSmithKline (GSK), is set to spend £500 million on a new state-of-the-art biopharmaceutical manufacturing plant and on improving its facility in Ware, Hertfordshire. The move comes after a pre-Budget report reduced the rate of Corporation Tax on 10pc on income arising from UK patents.
It seems that over the past few months, GSK and the drug industry have been in talks with the government about the proposal, which has been labeled a “patent box”. Speaking of the ‘patent box’, Andrew Witty, chief executive of GSK, said: “The patent box is exactly the sort of active, long-term and creative support that we need from the Government to ensure that the UK remains an attractive place for highly skilled sectors such as pharmaceuticals. For GSK, assuming the new regime will apply to patents currently under development it will have the immediate impact of making the UK a priority area for future investments, particularly in manufacturing.”
There is much speculation regarding the location of the biopharma site, but Stevenage, Ulverston and Barnard Castle, where the company has existing sites, are all in the running. Products that could be developed there include Arzerra, for leukaemia, and Syncria, for type 2 diabetes.
This investment is GSK’s largest in the UK for at least a decade and highlights the impact that the new tax regime could have on companies investing in research and development. To read more about this story, please visit the Telegraph website.
CK Science is proud to assist world-class pharmaceutical companies such as GSK to recruit talented individuals. To search for your next science job, please click here.